Develops Revita, a gut-targeting procedure, and Rejuva, a pancreatic gene therapy platform, for people with obesity or type two diabetes and the physicians and health systems treating them.
10-K for FY2025, filed Mar 24, 2026We are a clinical stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (“T2D”).…View ↗
The Revita DMR System (“Revita”), our lead product candidate, is based on our insights surrounding the potential role of the gut in…View ↗
We are also developing Rejuva, our novel and locally administered, adeno-associated virus (“AAV”)-delivered pancreatic gene therapy…View ↗
We believe Revita and Rejuva, if approved, have the potential to offer clinical and economic benefits while reducing the burden of disease…View ↗
Revita has had a limited pilot commercial launch in Germany. For a potential U.S. launch, Fractyl plans to work through gastrointestinal endoscopists at centers of excellence and a potential physician-driven platform partner; it also identifies patients, referring physicians, providers and payors as stakeholders.
10-K for FY2025, filed Mar 24, 2026To date, we have generated revenue in Germany since the limited pilot commercial launch of Revita in the first quarter of 2023. We have not…View ↗
If Revita is approved in the U.S. for a weight maintenance indication, we plan to execute an efficient “hub-and spoke” commercialization…View ↗
We believe Revita and Rejuva, if approved, have the potential to offer clinical and economic benefits while reducing the burden of disease…View ↗
8-K, filed Oct 22, 2026
BURLINGTON, Mass., October 22, 2026 (GLOBE NEWSWIRE) – Fractyl Health, Inc. (Nasdaq: GUTS) (the Company or Fractyl), a clinical-stage…View ↗
8-K, filed Sep 11, 2026
As previously disclosed, on March 13, 2026, Fractyl Health, Inc. (the “Company”) received a letter from the Listing Qualifications…View ↗
Loading...